Cognigenics is a pre-clinical cognitive neuroengineering company focused on developing and commercializing breakthrough biologics that will dramatically improve the lives of people with mental disorders.

Our first product will use CRISPR-based neuroengineering methods to treat chronic anxiety and depression. We have achieved proof-of-principle in mice that our design can noninvasively deliver edits to neuronal receptors, resulting in significant reductions in anxiety.

Follow-on experiments, for which we are raising Series A funds, will test dose and timing effects, variations in efficacy targeting different receptors, and then safety and toxicology pending IND submission to the FDA. We anticipate beginning clinical trials in 2 years.

Our R&D pipeline strategy is typical for an early-stage biopharmaceutical company: develop and move a lead asset into the clinic and develop and advance multiple, follow-on assets with enhanced properties and expanded applications.

We are also at the early stages of designing neurogenetic therapies for dementia and potentially Alzheimer’s disease. Our longer-term goal is to provide cognitive, perceptual, and memory enhancements for healthy individuals. All of our therapies in humans will be based on RNA edits, so there are no permanent (DNA) changes to brain function.

Our principals collectively have over a century of experience managing product development, neuroscience laboratories, biotech start-ups and pharmaceutical companies.

Cognigenics is a pre-clinical cognitive neuroengineering company focused on developing and commercializing breakthrough biologics that will dramatically improve the lives of people with mental disorders.

Our first product will use CRISPR-based neuroengineering methods to treat chronic anxiety and depression. We have achieved proof-of-principle in mice that our design can noninvasively deliver edits to neuronal receptors, resulting in significant reductions in anxiety.

Follow-on experiments, for which we are raising Series A funds, will test dose and timing effects, variations in efficacy targeting different receptors, and then safety and toxicology pending IND submission to the FDA. We anticipate beginning clinical trials in 2 years.

Our R&D pipeline strategy is typical for an early-stage biopharmaceutical company: develop and move a lead asset into the clinic and develop and advance multiple, follow-on assets with enhanced properties and expanded applications.

We are also at the early stages of designing neurogenetic therapies for dementia and potentially Alzheimer’s disease. Our longer-term goal is to provide cognitive, perceptual, and memory enhancements for healthy individuals. All of our therapies in humans will be based on RNA edits, so there are no permanent (DNA) changes to brain function.

Our principals collectively have over a century of experience managing product development, neuroscience laboratories, biotech start-ups and pharmaceutical companies.